Building Blocks Catalog

284 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

210 Million novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Compound Libraries

Over 60 pre-plated libraries in stock

Fast delivery

Library Synthesis

36B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

MedChem Highlights

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from May 2023

SF5-Building Blocks
Heterocyclic scaffolds
Piperazine Bioisosteres
Saturated Bioisosteres
Morpholine Bioisosteres
Diazirines
P(O)Me2-containing BBs
Oxetanes

Recent News

  • 22 May 2023   Press Releases

    Enamine Launches a New Chemistry Site in Germany

    Welcome to the latest update from Enamine - we're delighted to share our growth story with you. In our continued pursuit of scientific excellence and global expansion, we've launched a new subsidiary, Enamine Germany GmbH, based in Frankfurt's Höchst Industrial Park. This significant development strengthens our commitment to provide more localized and efficient services in organic synthesis and medicinal chemistry.

  • 27 April 2023   Press Releases

    Nostrum Biodiscovery and ENAMINE Join Forces to Develop a ...

    Barcelona, Spain, and Kyiv, Ukraine, April 27, 2023. Nostrum Biodiscovery, a leading provider of computational drug discovery services, and ENAMINE, a global supplier of chemical building blocks and screening compounds, announced today a groundbreaking collaboration for the co-development of a revolutionary search engine tailored for the REAL Space billion database. This partnership aims to deliver unparalleled performance in searching vast chemical spaces while utilizing low computational resources, thus increasing the efficiency and accessibility of drug discovery efforts.

    The collaboration will also focus on enhancing High Throughput Virtual Screening (HTVS) services to streamline the drug discovery process. Nostrum Biodiscovery's state-of-the-art AI-enabled screening platform will take center stage in this effort, boasting the capability to evaluate the entire billion compound collection in just hours. This innovative technology promises to identify potential drug candidates within weeks, significantly accelerating the discovery pipeline.

    ENAMINE’s expertise in the rapid and reliable provision of compounds will further strengthen the collaboration, ensuring that researchers have timely access to the vast array of molecules in the REAL Space database. This partnership will facilitate the seamless integration of Nostrum Biodiscovery's computational prowess with ENAMINE’s extensive compound collection, directly impacting companies interested in using services offered by both partners and ultimately benefiting the global scientific community and accelerating the path to new drug discoveries.

    [Victor Guallar, CSO Nostrum Biodiscovery] “We see it every day in our projects, using the REAL Space database with our AI/MM hybrid HTVS platform is a game changer in finding molecules. Our joint venture with ENAMINE demonstrates our commitment to integrating cutting-edge technology and high-quality compound collections to provide the pharmaceutical industry with unparalleled access to resources that expedite drug discovery. We believe that this partnership will serve as a catalyst for innovation, inspiring ventures to explore uncharted territories in the quest for novel therapeutics.”

    [Andrey Tarnovskiy, Sales Director, Europe at Enamine] “This year the size of Enamine’s REAL Space has reached tremendous 36 Billion compounds. We are excited to cooperate with Nostrum Biodiscovery to complement the available suite of search tools for REAL Space exploration with brand-new AI-based solution for high-throughput virtual screening and hope that our synergy will allow to facilitate and strengthen the drug discovery efforts of our customers.”

    Read Press Release

  • 19 April 2023   Press Releases

    Enamine and Endogena Therapeutics – a Successful, Multi-Year Drug ...

    Kyiv, Ukraine, April 19, 2023 - Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinicalstage biotech company focused on the development of endogenous regenerative medicines.

    Enamine provides Endogena with its integrated capability in medicinal chemistry to support Endogena’s small molecule drug discovery programs in the fields of hit finding, hit-to-lead and lead optimization.

    The companies have been collaborating under a Full Time Equivalent (FTE) model since 2019. The two discovery partners have been continuing their research collaboration to date, their research relationship not being impacted by the war in Ukraine. This collaboration extension, along with many others and new ones established by Enamine since February 24, 2022, already under the conflict, is a systematic positive trend experienced by the company, that demonstrates the support of its customers and the trust they have in receiving high-quality service backed up by the unparalleled number of diverse building blocks available at Enamine.

    Sven Weiler, Vice President of Medicinal Chemistry at Endogena, commented: “The interaction with colleagues from Enamine has been a smooth one from the start. In addition to the FTE model, it is great to have access to their huge compound collection and be able to flexibly use Enamine’s capacity to its full potential. We value the output and responsiveness of the Enamine team, helping us to achieve our demanding milestones. It is stunning to see how well Enamine has been able to keep pace after February 2022.”

    Michael Bossert, Head of Strategic Alliances at Enamine, added: “After 13 months of the war in the country, we are especially pleased to announce our collaboration with Endogena, a longlasting partner we have been serving during those several years with extensive medicinal chemistry and SAR efforts”.

    Read Press Release

View all Press Releases

Upcoming events

  • Sep 3-7

    Delegation

    EFMC-ASMC 2023

  • Jul 5-7

    Delegation

    RICT 2023

  • Jun 18-22

    Sponsoring

    International Summer School on Organic Synthesis "A. Corbella" - ISOS 2023

View calendar

Enamine is a reliable partner for compound collection enhancement (CCE) programs providing a full cycle of services from development of the initial concept in close collaboration with customer and synthesis of the scaffolds to parallel chemistry and compound management of the library compounds.

We offer:

  • Business model adaptable for each customer – fee-for-service, FTE-based or mixed.
  • Flexible design – based on the customer’s template(s) or our own scaffold collection, or focused on special compound classes such as covalent ligands or macrocycles. We can reshape the compound collection using advanced chemoinformatics tools according to virtually any selection criteria.
  • Diversity and speed – we can rely on the world’s largest collection of stock Building Blocks (around 200K) to construct the target cores and to decorate them.
  • Experience – we are highly skilled in both parallel chemistry and complex multistep synthetic projects, with >2 000 customers varying from small biotech and academia to big pharma.
  • Quality control and logistics – we perform reversed-phase preparative HPLC purification on all synthesized compounds to assure they meet purity requirements (usually 90% or 95% pure). Their quality is controlled with LCMS and up to 100% with 1H NMR. The compounds can be delivered in virtually any containers, including those received from a customer and assay-ready plates for immediate screening.

Please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. for more information and quotes on our service.

Bioactive Compounds

Versatile product to use in Drug Discovery

1 454 compounds

Our unique collection of 1 454 bioactive and reference substances were carefully collected, verified by cross-references and supported with full description for each molecule.

Request

  • All activity data are supported for each compound including references to the sources.
  • Includes enzyme inhibitors, receptor ligands, and ion channel regulators. Specific focused subsets on target types and therapeutic areas are available.
  • Do not contain FDA-approved drugs.
  • Covers various activity areas, such as GPCRs, Transporters, Ion Channels, Immuno-Oncology, Microbiology and Virology, Inflammation, Kinases etc.
  • Detailed compound information with structure, target, activity, and brief description.
  • All compounds purified by HPLC, purity confirmed by NMR and HP-LCMS analytical data.

Therapeutic areas

Target distribution

Catalog ID
Compounds
Amount
Formats
Price

Catalog #

BAC-1454-0-Y-10

# of compounds

1 454

Amount

Assay-ready plates,
≤ 2 µL of 10 mM
DMSO solutions

Plates and format

384-well plates, 320 compounds per plate,
first two and last two columns empty

Request a quote

Request a quote

Catalog #

BAC-1454-50-X-10

# of compounds

1 454

Amount

50 µL of 10 mM
DMSO stock solutions

Plates and format

384-well or 96-well plates:
first and last columns empty

Request a quote

Request a quote

*Y - 384-well plate
*X - 96-well plate

Fragments with confirmed aqueous solubility

Ultimate tool for fragment screening

7 500 compounds

Solubility is critically important for fragment-based screening; assured solubility of fragments at high concentrations can prevent a number of issues during the screening procedure. We have confirmed experimentally aqueous solubility for 7 500 fragments in standard phosphate buffer at 1 mM; measurements were performed using nephelometry-based method. Representative subset of 3 000 compounds was designed using multi-vectoral diversity selection.

Key features:

  • High structural diversity was achieved via two approaches: diversity selection using fingerprint-based Tanimoto distance and molecular framework frequency analysis. Compounds bearing trivial and abundant chemotypes were removed to enhance novelty of the set.
  • Guaranteed aqueous solubility at 1 mM in PBS buffer and at 200 mM in DMSO
  • Soluble Fragment Diversity Set can be readily followed with analogues either from stock or from validated syntheses. All required building blocks are available from Enamine stock.

Examples of the molecules in the library

Z1836338670

Z381041234

Z1255404894

Z2235681460

Z2001336017

Z1348554032

Z2217052350

Z1551916919

DKK-1 Inhibitors library

#

3 010 compounds

We used both docking and ligand-based approaches to assemble this subset. Specifically, the DKK1/LRP6 protein-protein interaction (PPI) interface was utilized to select matching ligands from our selection of drug-like compounds (4 032 162 total available molecules). For the docking approach we took into consideration data on analogues of NCI8642, a reported DKK-1/LRP6 interaction inhibitor. Specifically, we focused our design on topological and charge distribution features of the critical Dkk-1 loop that binds to LRP6. We reasoned that blocking/destabilizing this loop feature of the DKK-1/LRP6 PPI may yield modulators and/or activators of Wnt signaling while maintaining ‘normal’ Wnt-Fz-LRP6 signaling.

Fig. 1.Binding interface between LRP6 protein and representative ligand from the focused subset.

For the ligand-based approach we used known DKK-1 inhibitor WAY 262611.

Total library size is 3 014 lead-like compounds.

Fig. 2.(a) Pharmacophore model based on WAY-316606; orange – aromatic/heteroaromatic groups, green-hydrophobic pharmacophore (halogen, CF 3, CHF 2, Me, Et, iPr etc.), blue-positively charged moiety ( +NH 3Alk, +NH 2Alk 2, +NHAlk 3etc.); (b) Superposition of WAY-316606 and our pharmacophore construct used in (sub)library design.

[submenu-wnt-lib][/submenu-wnt-lib]

sp3 Rich Fragment Library

The world-largest and most diverse

50 272 compounds

Since 2000s, when the “Escape from Flatland” concept implying increase of saturation degree (Fsp3) and presence of chiral centers was introduced, numerous medicinal chemistry projects involving design and screening of sp3-enriched structures have appeared.

sp3 rich Fragments have been selected from Enamine Screening & Building Blocks Collections by applying strict Ro3 criteria, with Fsp3 cutoff at 0.47, and standard industry affiliated filters including PAINS. The final set of compounds has been evaluated to exclude simple reagents and trivial chemotypes resulting in a library of over 50 272 small molecules available for cherry-picking. Since the fragments with aromatic moieties are believed to demonstrate improved hit rate in screening, the set was enriched with compounds having the optimal Fsp3 values (0.47–0.75).

Novelty, high chemical and structural diversity of Enamine's sp3 rich fragments will make more efficient any search of new ligands for challenging targets.

Request

Examples of the molecules

Z802560076

Z2242859898

Z1685769805

Z2231941544

Z1392744361

Z1686200032

Z2125398654

Z2069795428

Z444353394

Z2146654607

Z1913963417

Z2438422350

FOLLOW US